Daxdilimab Biosimilar – Anti-LILRA4 mAb – Research Grade

Description of Daxdilimab Biosimilar - Anti-LILRA4 mAb - Research Grade

Introduction

Daxdilimab Biosimilar, also known as Anti-LILRA4 mAb, is a research-grade antibody that has shown promising potential as a therapeutic agent in various diseases. In this article, we will provide a detailed scientific description of Daxdilimab Biosimilar, including its structure, activity, and potential applications.

Structure of Daxdilimab Biosimilar

Daxdilimab Biosimilar is a monoclonal antibody that specifically targets LILRA4, a cell surface receptor involved in immune regulation. It is a fully humanized IgG1 antibody, meaning it is derived from human cells and has a constant region of the immunoglobulin G1 isotype. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The heavy chains are composed of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain one constant domain (CL) and one variable domain (VL).

Activity of Daxdilimab Biosimilar

Daxdilimab Biosimilar binds to LILRA4 with high affinity and specificity, inhibiting its function and downstream signaling pathways. LILRA4 is expressed on various immune cells, including monocytes, macrophages, and dendritic cells, and plays a crucial role in regulating immune responses. By targeting LILRA4, Daxdilimab Biosimilar can modulate immune cell activity and potentially treat diseases associated with dysregulated immune responses.

Mechanism of Action

Upon binding to LILRA4, Daxdilimab Biosimilar blocks the interaction between LILRA4 and its ligands, which include major histocompatibility complex (MHC) class I molecules and the extracellular matrix protein, osteopontin. This prevents the activation of downstream signaling pathways, such as the PI3K-Akt and MAPK pathways, which are involved in cell proliferation and survival. Additionally, Daxdilimab Biosimilar can also induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of LILRA4-expressing cells.

Potential Applications of Daxdilimab Biosimilar

Daxdilimab Biosimilar has shown promising results in preclinical studies and has the potential to be used in various disease indications.

Cancer

LILRA4 has been implicated in the progression of various types of cancer, including breast, lung, and colon cancer. By targeting LILRA4, Daxdilimab Biosimilar can inhibit tumor growth and survival, making it a potential therapeutic option for cancer treatment.

Autoimmune Diseases

LILRA4 has also been linked to the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Daxdilimab Biosimilar can modulate the activity of immune cells involved in these diseases, potentially providing a new treatment option for patients.

Inflammatory Disorders

Inflammation plays a crucial role in the pathogenesis of various disorders, including atherosclerosis and inflammatory bowel disease. By targeting LILRA4, Daxdilimab Biosimilar can regulate the activity of immune cells and reduce inflammation, making it a potential therapeutic agent for these conditions.

Infectious Diseases

LILRA4 has been shown to play a role in the immune response to viral and bacterial infections. By targeting LILRA4, Daxdilimab Biosimilar can modulate immune cell activity and potentially improve the immune response to these infections.

Future Directions

Daxdilimab Biosimilar is currently in preclinical development, and further studies are needed to determine its safety and efficacy in humans. However, the promising results from preclinical studies suggest that Daxdilimab Bios